English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Monday, March 14, 2022
IND Application for SinoMab's First-in-Class Asthma Therapeutic Product SM17 Approved by FDA
Thursday, February 17, 2022
IND Application for SinoMab's First-in-Class Asthma Therapeutic Product SM17 Accepted by FDA
Wednesday, February 16, 2022
中国抗体用于哮喘的第一类治疗产品SM17新药研究申请获FDA受理
中國抗體用於哮喘的第一類治療產品SM17新藥研究申請獲FDA受理
Monday, February 7, 2022
中国抗体公布SN1011新药研究申请获中国国家药品监督管理局药品审评中心受理
中國抗體公佈SN1011新藥研究申請獲中國國家藥品監督管理局藥品審評中心受理
SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE
Tuesday, January 11, 2022
中国抗体荣获“第六届金港股”评选中“最佳中小市值公司”、“最佳CEO”奖项及“2021新浪财经金麒麟最佳港美股上市公司”评选中“最具成长潜力上市公司”奖项
中國抗體榮獲「第六屆金港股」評選中「最佳中小市值公司」、「最佳CEO」獎項及「2021新浪財經金麒麟最佳港美股上市公司」評選中「最具成長潛力上市公司」獎項
SinoMab Awarded the "Best Small and Mid-Cap Company" and "Best CEO" in the Selection of the "6th Hong Kong Golden Stocks Awards" and the "Listed Company with the Most Growth Potential" in the Selection of "2021 Sina Finance Golden Unicorn Best Hong Kong and US Listed Companies"

Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575